特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

化学療法誘発性血小板減少症(CIT)- 疫学予測 2028年

Chemotherapy-induced thrombocytopenia (CIT) - Epidemiology Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 915398
出版日 ページ情報 英文 66 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.98円で換算しております。
化学療法誘発性血小板減少症(CIT)- 疫学予測 2028年 Chemotherapy-induced thrombocytopenia (CIT) - Epidemiology Forecast - 2028
出版日: 2019年11月01日 ページ情報: 英文 66 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における化学療法誘発性血小板減少症(CIT)の2017年の罹患数は30万2,735人と推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における化学療法誘発性血小板減少症(CIT)市場を調査し、疾病の概要、疫学的予測、罹患数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

目次

第1章 重要洞察

第2章 市場の概要:化学療法誘発性血小板減少症(CIT)

  • 市場シェアと分布(実数値)
  • 市場シェアと分布(予測値)

第3章 疾病概要:化学療法誘発性血小板減少症(CIT)

  • イントロダクション
  • 分類
  • 兆候と症状
  • 評価方式
  • 臨床的アプローチ
  • 血小板生成プロセス
  • 病態生理
  • 血栓形成の可能性がある生物製剤
  • 診断

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の罹患数
  • 国別の疫学
  • 米国
    • 仮定と根拠
    • 化学療法誘発性血小板減少症(CIT)の罹患数
    • 化学療法誘発性血小板減少症(CIT)の罹患数:化学療法薬別
  • EU5カ国
    • ドイツ
      • 化学療法誘発性血小板減少症(CIT)の罹患数
      • 化学療法誘発性血小板減少症(CIT)の罹患数:化学療法薬別
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本
    • 化学療法誘発性血小板減少症(CIT)の罹患数
    • 化学療法誘発性血小板減少症(CIT)の罹患数:化学療法薬別

第5章 アンメットニーズ

第6章 市場の成長要因

第7章 市場の障壁

第8章 付録

第9章 レポート方法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1 WHO Bleeding Scale
  • Table 2 Summary of the Modified WHO Bleeding Scale
  • Table 3 The Bleeding Severity Measurement Scale by Webert et al. (2012)
  • Table 4 Differential diagnosis of Thrombocytopenia according to clinical scenario
  • Table 5 Incident Cases of Chemotherapy-induced thrombocytopenia in 7MM (2017-2028)
  • Table 6 Incident Cases of Chemotherapy-induced thrombocytopenia in the US (2017-2028)
  • Table 7 Incidence of CIT by Chemotherapeutic Agent in the United States (2017-2028)
  • Table 8 Incident Cases of Chemotherapy-induced thrombocytopenia in Germany (2017-2028)
  • Table 9 Incidence of CIT by Chemotherapeutic Agent in Germany (2017-2028)
  • Table 10 Incident Cases of Chemotherapy-induced thrombocytopenia in France (2017-2028)
  • Table 11 Incidence of CIT by Chemotherapeutic Agent in France (2017-2028)
  • Table 12 Incident Cases of Chemotherapy-induced thrombocytopenia in Italy (2017-2028)
  • Table 13 Incidence of CIT by Chemotherapeutic Agent in Italy (2017-2028)
  • Table 14 Incident Cases of Chemotherapy-induced thrombocytopenia in Spain (2017-2028)
  • Table 15 Incidence of CIT by Chemotherapeutic Agent in Spain (2017-2028)
  • Table 16 Incident Cases of Chemotherapy-induced thrombocytopenia in the UK (2017-2028)
  • Table 17 Incidence of CIT by Chemotherapeutic Agent in the UK (2017-2028)
  • Table 18 Incident Cases of Chemotherapy-induced thrombocytopenia in Japan (2017-2028)
  • Table 19 Incidence of CIT by Chemotherapeutic Agent in Japan (2017-2028)

List of Figures

  • Figure 1: Classification of Thrombocytopenia
  • Figure 2: NCI Grading of Thrombocytopenia
  • Figure 3: The Production of Platelets from Bone Marrow Stem Cells
  • Figure 4: Incident Cases of Chemotherapy-induced thrombocytopenia in 7MM (2017-2028)
  • Figure 5: Incident Cases of Chemotherapy-induced thrombocytopenia in the US (2017-2028)
  • Figure 6: Incidence of CIT by Chemotherapeutic Agent in the United States (2017-2028)
  • Figure 7: Incident Cases of Chemotherapy-induced thrombocytopenia in Germany (2017-2028)
  • Figure 8: Incidence of CIT by Chemotherapeutic Agent in Germany (2017-2028)
  • Figure 9: Incident Cases of Chemotherapy-induced thrombocytopenia in France (2017-2028)
  • Figure 10: Incidence of CIT by Chemotherapeutic Agent in France (2017-2028)
  • Figure 11: Incident Cases of Chemotherapy-induced thrombocytopenia in Italy (2017-2028)
  • Figure 12: Incidence of CIT by Chemotherapeutic Agent in Italy (2017-2028)
  • Figure 13: Incident Cases of Chemotherapy-induced thrombocytopenia in Spain (2017-2028)
  • Figure 14: Incidence of CIT by Chemotherapeutic Agent in Spain (2017-2028)
  • Figure 15: Incident Cases of Chemotherapy-induced thrombocytopenia in the UK (2017-2028)
  • Figure 16: Incidence of CIT by Chemotherapeutic Agent in the UK (2017-2028)
  • Figure 17: Incident Cases of Chemotherapy-induced thrombocytopenia in Japan (2017-2028)
  • Figure 18: Incidence of CIT by Chemotherapeutic Agent in Japan (2017-2028)
  • Figure 19: Unmet Needs
  • Figure 20:Market Drivers
  • Figure 21:Market Barriers
目次
Product Code: DIEI0388

DelveInsight's 'Chemotherapy-induced thrombocytopenia (CIT)-Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Chemotherapy-induced thrombocytopenia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Chemotherapy-induced thrombocytopenia - Disease Understanding

Thrombocytopenia can be defined as the deficiency of platelets (thrombocytes) that increase the risk of bleeding. Platelets maintain vascular endothelium integrity and control hemorrhage control following small-vessel injury by platelet plug formation and provide a firm, stable, fibrin clot in large injury. In Thrombocytopenia, the platelet count of patients drops down to less than 150 × 103 per µL.

The National Cancer Institute Common Toxicity Criteria defines Chemotherapy-induced thrombocytopenia (CIT) as a platelet count of fewer than 75,000 cells/µL, with the risk of bleeding, complications increase with lower platelet counts. However, there is no standard definition of CIT, it depends mostly on the observed platelet count reduction in clinical settings. It is a frequent complication associated with cancer therapy and the decrease in platelet count persists despite adequate recovery time from prior chemotherapy nadir, in the context of recovery of white cells and red cells.

The chemotherapy has improved the outcome of several cancers but is associated with various adverse effects (due to the cytotoxic nature), including hematological toxicities. The loss of platelets during chemotherapy called CIT is dose-limiting for chemotherapy treatment.

Chemotherapy-induced thrombocytopenia - Epidemiology

The Chemotherapy-induced thrombocytopenia epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the incident pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident cases of CIT and Total Incidence of CIT by Chemotherapeutic Agents) scenario of Chemotherapy-induced thrombocytopenia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total Incident cases of Chemotherapy-induced thrombocytopenia (CIT) in the 7MM was found to be 302,735 in 2017. The incidence of Chemotherapy-induced thrombocytopenia in the 7MM is expected to increase during the study period of 2017-2028.

Among 7MM, the United States has the highest incident cases of Chemotherapy-induced thrombocytopenia with about 114,782 cases in 2017. Among EU-5 countries, Germany had the highest number of incident cases with approximately 35,594 cases, followed by France. Spain had the least number of incident cases, while in Japan, the incident cases of Chemotherapy-induced thrombocytopenia was found to be approximately 60,682.

Chemotherapy-induced thrombocytopenia Report Insights

  • The report covers a descriptive overview of Chemotherapy-induced thrombocytopenia, explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology Chemotherapy-induced thrombocytopenia in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.

Chemotherapy-induced thrombocytopenia Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Total Incident case of Chemotherapy-induced thrombocytopenia
  • Total Incident case of Chemotherapy-induced thrombocytopenia by Chemotherapeutic Agents

Chemotherapy-induced thrombocytopenia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles

Key Benefits

  • Key assessments
  • Disease Risk & Burden
  • Risk of disease by Grade

Table of Contents

1. Key Insights

2. Chemotherapy-induced Thrombocytopenia: Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Chemotherapy-induced Thrombocytopenia in 2017
  • 2.2. Market Share (%) Distribution of Chemotherapy-induced Thrombocytopenia in 2028

3. Disease Overview: Chemotherapy-induced thrombocytopenia (CIT)

  • 3.1. Introduction
  • 3.2. Thrombocytopenia-Classification
  • 3.3. Signs and Symptoms
  • 3.4. Grading System
  • 3.5. Clinical approach to Thrombocytopenia
  • 3.6. Process of Platelet Genesis and Platelet Production
  • 3.7. Pathophysiology
  • 3.8. Biologics with Thrombopoietic Potential
  • 3.9. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Incident Cases of Chemotherapy-induced thrombocytopenia
  • 4.3. Country Wise-Epidemiology of Chemotherapy-induced thrombocytopenia
  • 4.4. United States
    • 4.4.1. Assumptions and Rationale
    • 4.4.2. Incident Cases of Chemotherapy-induced thrombocytopenia in the United States
    • 4.4.3. Incidence of CIT by Chemotherapeutic Agent in the United States
  • 4.5. EU5
  • 4.6. Assumptions and Rationale
  • 4.7. Germany
    • 4.7.1. Incident Cases of Chemotherapy-induced thrombocytopenia in Germany
    • 4.7.2. Incidence of CIT by Chemotherapeutic Agent in Germany
  • 4.8. France
    • 4.8.1. Incident Cases of Chemotherapy-induced thrombocytopenia in France
    • 4.8.2. Incidence of CIT by Chemotherapeutic Agent in France
  • 4.9. Italy
    • 4.9.1. Incident Cases of Chemotherapy-induced thrombocytopenia in Italy
    • 4.9.2. Incidence of CIT by Chemotherapeutic Agent in Italy
  • 4.10. Spain
    • 4.10.1. Incident Cases of Chemotherapy-induced thrombocytopenia in Spain
    • 4.10.2. Incidence of CIT by Chemotherapeutic Agent in Spain
  • 4.11. United Kingdom
    • 4.11.1. Incident Cases of Chemotherapy-induced thrombocytopenia in the UK
    • 4.11.2. Incidence of CIT by Chemotherapeutic Agent in the UK
  • 4.12. Japan
    • 4.12.1. Assumptions and Rationale
    • 4.12.2. Incident Cases of Chemotherapy-induced thrombocytopenia in Japan
    • 4.12.3. Incidence of CIT by Chemotherapeutic Agent in Japan

5. Unmet Needs

6. Market Drivers

7. Market Barriers

8. Appendix

9. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight